We are live on
!
Find out more
CPH
C Partners Holding Portfolio holdings
AUM
$317M
1-Year Est. Return
4.76%
This Fund
S&P 500
This Quarter
Est. Return
+1.57%
1 Year Est. Return
-4.76%
3 Year Est. Return
+31.57%
5 Year Est. Return
+26.92%
10 Year Est. Return
+222.73%
AUM
$309M
AUM Growth
–
Cap. Flow
+$302M
Cap. Flow
% of AUM
97.95%
Top 10 Holdings %
Top 10 Hldgs %
65.87%
Holding
49
New
48
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPDR Gold Trust
GLD
|
+$110M |
| 2 |
ADMS
Adamas Pharmaceuticals
ADMS
|
+$30.5M |
| 3 |
Royal Gold
RGLD
|
+$13M |
| 4 |
Wheaton Precious Metals
WPM
|
+$12M |
| 5 |
Johnson & Johnson
JNJ
|
+$7.29M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.25% |
| 2 | Materials | 12.77% |
| 3 | Consumer Discretionary | 6% |
| 4 | Technology | 4.04% |
| 5 | Consumer Staples | 2.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
MSC Industrial Direct
MSM
$6.89B
| $3.91M | 1.27% |
+48,144
| New | +$3.92M |
|
27
Alphabet (Google) Class C
GOOG
$4.36T
| $3.75M | 1.21% |
+142,169
| New | +$3.81M |
|
|
CELG
28
DELISTED
Celgene Corp
CELG
| $3.47M | 1.12% |
+31,000
| New | +$3.27M |
|
29
Viatris
VTRS
$20.4B
| $3.27M | 1.06% |
+58,000
| New | +$3.11M |
|
30
Gilead Sciences
GILD
$162B
| $3.07M | 1% |
+32,600
| New | +$3.37M |
|
31
Abbott
ABT
$183B
| $2.35M | 0.76% |
+52,137
| New | +$2.27M |
|
32
Biogen
BIIB
$30B
| $1.73M | 0.56% |
+5,100
| New | +$1.65M |
|
33
AbbVie
ABBV
$443B
| $1.7M | 0.55% |
+26,000
| New | +$1.64M |
|
34
Cardinal Health
CAH
$53.9B
| $1.7M | 0.55% |
+21,000
| New | +$1.66M |
|
|
PCYC
35
DELISTED
PHARMACYCLICS INC
PCYC
| $1.65M | 0.54% |
+13,500
| New | +$1.73M |
|
36
Pfizer
PFE
$143B
| $1.56M | 0.5% |
+52,700
| New | +$1.51M |
|
37
Teva Pharmaceuticals
TEVA
$40.8B
| $1.5M | 0.48% |
+26,000
| New | +$1.45M |
|
38
IQVIA
IQV
$38.7B
| $1.47M | 0.48% |
+25,000
| New | +$1.43M |
|
39
Revvity
RVTY
$12.6B
| $1.44M | 0.47% |
+33,000
| New | +$1.42M |
|
|
HPTX
40
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
| $1.42M | 0.46% |
+59,000
| New | +$1.33M |
|
41
Perrigo
PRGO
$1.4B
| $1.03M | 0.33% |
+6,162
| New | +$964K |
|
|
ELGX
42
DELISTED
Endologix Inc
ELGX
| $867K | 0.28% |
+5,672
| New | +$708K |
|
43
Thermo Fisher Scientific
TMO
$213B
| $789K | 0.26% |
+6,300
| New | +$766K |
|
44
Stryker
SYK
$125B
| $755K | 0.24% |
+8,000
| New | +$710K |
|
45
Boston Scientific
BSX
$69.5B
| $729K | 0.24% |
+55,000
| New | +$703K |
|
|
BDSI
46
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $661K | 0.21% |
+55,000
| New | +$836K |
|
|
RVNC
47
DELISTED
Revance Therapeutics, Inc.
RVNC
| $407K | 0.13% |
+24,000
| New | +$419K |
|
|
DVAX
48
DELISTED
Dynavax Technologies
DVAX
| $349K | 0.11% |
+20,697
| New | +$315K |
|
|
SCPX
49
DELISTED
Scorpius Holdings, Inc.
SCPX
| – | – |
0
| – | – |
|
Similar funds
KI
CPW
GWP
TM
WIS
CC
FNWM
GBFG
C Partners Holding's Q4 2014 Portfolio in Review
Q4 2014 is the first quarter with a 13F filing on record for C Partners Holding, which disclosed 49 positions worth $309M. Its ten largest holdings account for 66% of the portfolio.
Its largest position is SPDR Gold Trust: 953,500 shares worth $108M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, followed by Materials and Consumer Discretionary.
- C Partners Holding's largest Q4 2014 buy was SPDR Gold Trust: 953,500 shares worth $108M.
- C Partners Holding's ten largest holdings make up 66% of its $309M portfolio in Q4 2014.
- C Partners Holding disclosed 49 positions in Q4 2014, its first 13F filing on record.
Based on C Partners Holding's 13F filing for Q4 2014, filed 18 Feb 2015.